These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 14727242)

  • 1. Clinical trial of endorectal amifostine for radioprotection in patients with prostate cancer: rationale and early results.
    Ménard C; Camphausen K; Muanza T; Sears-Crouse N; Smith S; Ben-Josef E; Coleman CN
    Semin Oncol; 2003 Dec; 30(6 Suppl 18):63-7. PubMed ID: 14727242
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intrarectal application of amifostine for the prevention of radiation-induced rectal injury.
    Ben-Josef E; Han S; Tobi M; Vargas BJ; Stamos B; Kelly L; Biggar S; Kaplan I
    Semin Radiat Oncol; 2002 Jan; 12(1 Suppl 1):81-5. PubMed ID: 11917290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparing measures of acute bowel toxicity in patients with prostate cancer treated with external beam radiation therapy.
    Muanza TM; Albert PS; Smith S; Godette D; Crouse NS; Cooley-Zgela T; Sciuto L; Camphausen K; Coleman CN; Ménard C
    Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1316-21. PubMed ID: 16029787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intrarectal amifostine during external beam radiation therapy for prostate cancer produces significant improvements in Quality of Life measured by EPIC score.
    Simone NL; Ménard C; Soule BP; Albert PS; Guion P; Smith S; Godette D; Crouse NS; Sciuto LC; Cooley-Zgela T; Camphausen K; Coleman CN; Singh AK
    Int J Radiat Oncol Biol Phys; 2008 Jan; 70(1):90-5. PubMed ID: 17855015
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A pilot study of topical intrarectal application of amifostine for prevention of late radiation rectal injury.
    Ben-Josef E; Han S; Tobi M; Shaw LM; Bonner HS; Vargas BJ; Prokop S; Stamos B; Kelly L; Biggar S; Kaplan I
    Int J Radiat Oncol Biol Phys; 2002 Aug; 53(5):1160-4. PubMed ID: 12128116
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intrarectal amifostine suspension may protect against acute proctitis during radiation therapy for prostate cancer: a pilot study.
    Singh AK; Ménard C; Guion P; Simone NL; Smith S; Crouse NS; Godette DJ; Cooley-Zgela T; Sciuto LC; Coleman J; Pinto P; Albert PS; Camphausen K; Coleman CN
    Int J Radiat Oncol Biol Phys; 2006 Jul; 65(4):1008-13. PubMed ID: 16730138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amifostine and external beam radiation therapy and/or high-dose rate brachytherapy in the treatment of localized prostate carcinoma: preliminary results of a phase II trial.
    Linares LA; Echols D
    Semin Oncol; 2003 Dec; 30(6 Suppl 18):58-62. PubMed ID: 14727241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radiotherapy or chemotherapy followed by radiotherapy with or without amifostine in locally advanced lung cancer.
    Antonadou D
    Semin Radiat Oncol; 2002 Jan; 12(1 Suppl 1):50-8. PubMed ID: 11917285
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amifostine reduces radiochemotherapy-induced toxicities in patients with locally advanced non-small cell lung cancer.
    Antonadou D; Petridis A; Synodinou M; Throuvalas N; Bolanos N; Veslemes M; Sagriotis A
    Semin Oncol; 2003 Dec; 30(6 Suppl 18):2-9. PubMed ID: 14727235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rationale for a phase I/II radiation dose-escalation study with concurrent amifostine (Ethyol) and infusional 5-FU chemotherapy for preoperative treatment of unresectable or locally recurrent rectal carcinoma.
    Myerson R
    Semin Radiat Oncol; 2002 Jan; 12(1 Suppl 1):86-90. PubMed ID: 11917291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Feasibility of amifostine administration in conjunction with high-dose rate brachytherapy.
    Dziuk T; Senzer N
    Semin Oncol; 2003 Dec; 30(6 Suppl 18):49-57. PubMed ID: 14727240
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduction of treatment breaks and radiation-induced esophagitis and pneumonitis using amifostine in unresectable non-small cell lung cancer patients receiving definitive concurrent chemotherapy and radiation therapy: a prospective community-based clinical trial.
    Wynn RB; Mehta V
    Semin Oncol; 2005 Apr; 32(2 Suppl 3):S99-104. PubMed ID: 16015543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of dose and schedule on the efficacy of ethyol: preclinical studies.
    Cassatt DR; Fazenbaker CA; Kifle G; Bachy CM
    Semin Oncol; 2003 Dec; 30(6 Suppl 18):31-9. PubMed ID: 14727238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intermittent use of amifostine during postoperative radiochemotherapy and acute toxicity in rectal cancer patients.
    Dunst J; Semlin S; Pigorsch S; Müller AC; Reese T
    Strahlenther Onkol; 2000 Sep; 176(9):416-21. PubMed ID: 11050915
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II multicenter randomized study of amifostine for prevention of acute radiation rectal toxicity: topical intrarectal versus subcutaneous application.
    Kouloulias VE; Kouvaris JR; Pissakas G; Mallas E; Antypas C; Kokakis JD; Matsopoulos G; Michopoulos S; Mystakidou K; Vlahos LJ
    Int J Radiat Oncol Biol Phys; 2005 Jun; 62(2):486-93. PubMed ID: 15890591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Feasibility and efficacy of subcutaneous amifostine therapy in patients with head and neck cancer treated with curative accelerated concomitant-boost radiation therapy.
    Ozsahin M; Betz M; Matzinger O; Bron L; Luthi F; Pasche P; Azria D; Mirimanoff RO; Zouhair A
    Arch Otolaryngol Head Neck Surg; 2006 Feb; 132(2):141-5. PubMed ID: 16490870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The evaluation of amifostine for mucosal protection in patients with advanced loco-regional squamous cell carcinomas of the head and neck (SCCHN) treated with concurrent weekly carboplatin, paclitaxel, and daily radiotherapy (RT).
    Suntharalingam M; Jaboin J; Taylor R; Wolf J; Banglore M; Van Echo D; Ord R
    Semin Oncol; 2004 Dec; 31(6 Suppl 18):2-7. PubMed ID: 15726515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rationale for integrating high-dose rate intraoperative radiation (HDR-IORT) and postoperative external beam radiation with subcutaneous amifostine for the management of stage III/IV head and neck cancer.
    Hu K; Ship JA; Harrison LB
    Semin Oncol; 2003 Dec; 30(6 Suppl 18):40-8. PubMed ID: 14727239
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extended-field irradiation and intracavitary brachytherapy combined with cisplatin and amifostine for cervical cancer with positive para-aortic or high common iliac lymph nodes: results of arm II of Radiation Therapy Oncology Group (RTOG) 0116.
    Small W; Winter K; Levenback C; Iyer R; Hymes SR; Jhingran A; Gaffney D; Erickson B; Greven K
    Int J Gynecol Cancer; 2011 Oct; 21(7):1266-75. PubMed ID: 21892091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II randomized study of topical intrarectal administration of amifostine for the prevention of acute radiation-induced rectal toxicity.
    Kouloulias VE; Kouvaris JR; Pissakas G; Kokakis JD; Antypas C; Mallas E; Matsopoulos G; Michopoulos S; Vosdoganis SP; Kostakopoulos A; Vlahos LJ
    Strahlenther Onkol; 2004 Sep; 180(9):557-62. PubMed ID: 15378186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.